PMDAapproval72% confidence
[SHINSA]English Translation of Review Report: Blenrep, Neffy, and Tecentriq (Partial Change Approval)
Source: PMDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (asthma) as Breztri Gains US Approval as First Triple Therapy for Asthma.
Regulatory Analysis
PMDA document relevant to the signal.
Supporting Context
- Therapeutic area
- Respiratory · Asthma
- Sub-indication
- Asthma
Related signal: Breztri Gains US Approval as First Triple Therapy for Asthma